Get all your news in one place.
100's of premium titles.
One app.
Start reading
Barchart
Barchart
Pathikrit Bose

Should You Buy Caris Life Sciences Stock After the CAI IPO?

Initial public offerings (IPOs) just keep on coming in 2025 and they continue to remain in heavy demand. Companies have already raised about $25.4 billion through IPOs so far this year, exceeding the $18.2 billion raised in the same period in 2024. 

One of the latest companies to hit the public market is Caris Life Sciences (CAI). Pricing its IPO at $21 per share, Caris ended up debuting far above its initial estimates. 

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.